Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.
List view / Grid view
BioNTech acquires Kite’s solid tumour neoantigen T cell receptor research platform and Gaithersburg manufacturing facility for undisclosed amount.
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.